EMA committee favors approval of Livmarli for PFIC in EU
Note: This story was updated July 9, 2024, to clarify Livmarli is approved in the U.S. for all PFIC forms, but not recommended for a…
News
HealthWell Foundation opens fund for MASH patients in US
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
US doctors prescribe Rezdiffra, note concern about patient costs
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…
Livmarli helps Alagille patients stop other anti-itch meds in real world
About one year of treatment with Livmarli (maralixibat) allows about a third of patients with Alagille syndrome to stop at least one other…
Hepatitis C test-and-treat program works for migrants in Italy: Study
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…
Ocaliva shown to reduce markers of liver damage, scarring in PBC trial
Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…
Benefits of Livmarli for cholestasis sustained up to 2 years: Trial data
Up to two years of daily treatment with Livmarli (maralixibat) controlled itch and reduced blood levels of bile acids and bilirubin, two markers of…
Acute-on-chronic liver failure in BA linked to transplant complications
Children with biliary atresia who have a serious condition called acute-on-chronic liver failure (ACLF) tend to require a longer stay in the hospital and are…
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
Seladelpar eases liver damage, itch in primary biliary cholangitis
One year of treatment with Gilead Sciences’ seladelpar normalized biomarkers of liver injury and rapidly reduced itch for most people with primary biliary…
Recent Posts
- PBC treatment Ocaliva leaves U.S. market amid safety concerns
- When facing a hospital stay, pack a bag and hope for chocolate cake
- Hormone-like therapy NF-1 shows promise in ICP mouse study
- FDA weighs noninvasive biopsy alternative in MASH clinical trials
- Savoring the everyday moments that bring joy to our lives